ARJUN JUNEJA grew up playing cricket as a leg spinner, right from grade 4, and went on to play up to the state level. His love for cricket now reflects in the company’s marketing campaign which features former India captains Sourav Ganguly and Anil Kumble. Juneja joined Mankind Pharma in 2008. In FY23, the revenue stood at ₹8,749 crore.
The company is a leading player in the domestic pharmaceuticals space, especially in acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, anti diabetic, neuro/CNS, VMN and respiratory. In consumer healthcare, it operates in condoms, pregnancy detection, emergency contraceptives, among others. It has 28 manufacturing facilities across the country.
The company’s biggest brand is Nurokind (acute and chronic) valued at ₹579 crore with a market share of 14.45%. In chronic, its Telmikind ranks first with ₹554 crore and has a 10% share of the hypertension segment.
For Juneja personally, the inflection point came in 2009-10 when he started leading business development. “Cold calling randomly got us the first break with UCB (Union Chimiqe Belge) of Belgium, which offered us Longifene, an appetite stimulant for children, for marketing,” says Juneja. Eventually Mankind brought UCB’s india business. Another major inflection point was setting up R&D for Mankind in 2012 with a molecule called Dydroboon. The gamble paid off and Mankind became the second company in the world — after Abbott — to offer the infertility product for women. Juneja also led the company through its listing last year. — Gina Krishnan